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Background aims: After recent observations that intrathecal administration of autologous bone marrow mesenchymal stromal
cells (MSCs) increases cerebral metabolism in patients with severe traumatic brain injury (TBI), we examined this type of cell
therapy in Alzheimer’s type dementia. Methods: Three patients with clinical diagnosis of Alzheimer’s disease received every
3 months 100 million autologous MSCs by intrathecal route, until a total dose of 300 million. Results: During cell therapy the
patients showed arrest in neurological deterioration and two of them manifested clear improvement of previous symptoms.
A global increase in cerebral glucose metabolism, measured using 18F-fluorodeoxyglucose positron emission tomography
(18F-FDG-PET), was observed after every administration of cell therapy. Conclusions: Our present findings suggest that
intrathecal administrations of autologous MSCs can be a new strategy for the treatment of Alzheimer’s dementia.KeyWords: Alzheimer’s disease, brain metabolism, cell therapy, dementiaIntroduction
Alzheimer’s disease (AD) and related dementias rep-
resent fatal neurodegenerative disorders for which at
present we do not have an effective treatment. In
these patients, a decrease in brain glucose metabo-
lism is considered a crucial event related to cognitive
impairment [13]. For this reason, generally the
medications used in AD pursue an increase in brain
glucose metabolism [46].
Recently we reported that intrathecal administra-
tion of bone marrow mesenchymal stromal cells
(MSCs) in patients suffering from neurological dys-
function after severe traumatic brain injury (TBI)
can achieve a progressive increase in brain glucose
metabolism, measured using 18F-fluorodeoxyglucose
positron emission tomography (18F-FDG-PET), and
it can be associated with neurocognitive improvement
[7]. After these findings, we speculate that this type
of cell therapy could also be useful in AD and Alz-
heimer’s type dementias (ATD).Correspondence: Jesus Vaquero, MD, PhD, Neurosurgery Service, Hospital P
Madrid, Spain. E-mail: jvaqueroc@telefonica.net
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The Spanish Agency for Medicaments and Health
Products (EAMPS) and the Medical Management
of Puerta de Hierro-Majadahonda Hospital autho-
rized the intrathecal administration (into subarach-
noid space, through lumbar puncture) of our NC1
medicament in three patients with diagnosis of AD.
Ethical aspects and possible benefits were consid-
ered. The study was conducted in accordance with
the principles of the Declaration of Helsinki [8] and
good clinical practice guidelines [9]. Informed con-
sent was obtained, after explaining the experimental
nature of the treatment and the previous experience
obtained with intrathecal administration of our NC1
medicament in patients with neurological sequelae
due to spinal cord injury (SCI) [10].
NC1 is a cell therapy medicament developed in
our cleanroom of the neurosurgical service of the
Puerta de Hierro-Majadahonda Hospital, and is cur-
rently approved as a medicament under clinicaluerta de Hierro-Majadahonda, Joaquın Rodrigo 2, 28222-Majadahonda,
apy. Published by Elsevier Inc. This is an open access article under the CC
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12-141). It consists of expanded autologous MSCs
obtained from bone marrow and autologous plasma as
its excipient. Techniques for culture and expansion of
MSCs, phenotypic characterization, formulation and
packaging have been previously described [10,11] and
are summarized in the Supplementary Appendix. In
our medicament, MSCs have a viability always 95%
as established by our quality criteria, and this viability
remains constant for at least 10 h. The administration
of the cells through a lumbar puncture is a procedure
that only lasts about 10 min. Therefore, cell viability
remains the same after cell transplantation.
Clinical and neuroimage studies were performed
on our patients. Cerebral beta-amyloid neuritic pla-
ques were detected with 18F-Flutemetamol positron
emission tomography, and brain glucose metabolism
was studied using 18F-FDG-PET. Neuropsycholog-
ical studies included Mini Mental State Examination
(MMSE) scale [12], Rey Complex Figure Test
(CRFT) [13], Stroop test [14], Spanish adaptation
to California Verbal Learning Test (CVLT) [15] and
Wechler Adult Intelligence Scale (WAIS-III) [16].
Statistical study of neuropsychological scores was
performed using the non-overlap of all pairs (NAP)
test [17].Figure 1. PET studies in Case 1. (AC) Detection of beta-
amyloid neuritic plaques with 18F-Flutemetamol-PET. (DF)
18F-FDG-PET prior to cell therapy. This study showed hypome-
tabolism in the left parietotemporal territory, with involvement of
the precuneus and posterior cingulate. A decrease in glucose
uptake in the mesial region and anterior poles of both temporal
lobes with hippocampal territory affectation and a focal hypome-
tabolism on the right lateral temporal territory were also observed.
(GI) 18F-FDG-PET 1 week after the first intrathecal adminis-
tration of 100 million MSCs, showing a strong increase in cerebral
glucose metabolism.Report of cases
Case 1
A 65-year-old man, with more than 20 years of for-
mal education and family history of AD, was diag-
nosed with AD 2 years before coming to us to
evaluate for cell therapy treatment. At this moment,
he described a slow but progressive neurological
deterioration. In July 2017, he stopped taking his
medication (donepezil, 5 mg/d). Cell therapy was
administered between November 2017 and May
2018 (100 million MSCs every 3 months). At the
end of treatment, the patient and his family consid-
ered that he was stable, with no progression, but
without clear improvement of the symptoms previ-
ous to cell therapy. A neuropsychological assessment
was performed before the treatment (pre) and 2
weeks after each MSC dose (post 1, post 2 and post
3). The results showed a slight improvement in
MMSE [12]: pre, 27 points; post 1, 25; post 2, 28;
and post 3, 27; NAP= small effect. Short-term visual
memory [13] reached 12 points at the end of cell
therapy (post 3), being 9.5 points previous, 8 points
at post 1 and 8.5 points at post 2. However, there
were statistically significant improvements on long-
term visual memory [13]: pre, 6.5 points; post 1, 6
points; post 2, 8.5 points; and post 3, 8.5 points;
NAP =medium effect. Mental processing speed [16]showed the following: pre, 33 points; post 1, 38
points; post 2, 39 points; and post 3, 37 points;
NAP = strong effect. Inhibition of automatic
response [14] showed the following: pre, 49 points;
post 1, 48 points; post 2, 57 points; and post 3, 54
points; NAP =medium effect.
Studies with 18F-FDG-PET showed progressive
increases in global brain glucose metabolism during
cell therapy (Figure 1).Case 2
A 56-year-old man, with 20 years of formal educa-
tion and no familiy history of dementia, was diag-
nosed with AD 2 years before coming to us to
evaluate for cell therapy treatment. The patient had
not accepted medication for his cognitive problems,
except vitamin supplements. He related progressive
difficulties in his work, showing problems remember-
ing how to organize simple activities or manage easy
tasks on his computer. He also had exhibited several
spatial disorientation episodes. He received intrathe-
cal cell therapy between November 2017 and June
2018 (100 million MSCs every 3 months). In July
2018, after finishing cell therapy, the patient
430 J. Vaquero et al.mentioned an appreciable improvement in his daily
activities, especially using his computer and with no
other disorientation episodes. A neuropsychological
assessment was performed before the treatment
(pre) and 2 weeks after every MSC dose (post 1, post
2 and post 3). Neuropsychological examination
showed improvement in MMSE [12] (28 points, 27
points, 27 points and 30 points at prior, post 1, post
2 and after cell therapy, respectively; NAP = small
effect). Verbal learning [15] showed the following:
pre, 38 points; post 1, 59 points; post 2, 54 points;
and post 3, 59 points; NAP= strong effect. Verbal
short-term memory test [15] showed the following:
pre, 12 points; post 1, 14 points; post 2, 14 points;
and post 3, 14 points; NAP= strong effect. Verbal
long-term memory test [15] showed the following:
pre, 10 points; post 1, 13 points; post 2, 13 points;
and post 3, 14 points; NAP = strong effect. Attention
[16] showed the following: pre, 12 points; post 1, 13
points; post 2, 16 points; and post 3, 15 points;
NAP = strong effect. Mental processing speed [16]
showed the following: pre, 56 points; post 1, 59
points; post 2, 73 points; and post 3, 72 points;
NAP = strong effect. Study of the inhibition of auto-
matic response [14] showed the following: pre, 50
points; post 1, 46 points; post 2, 49 points; and post
3, 57 points; NAP = small effect.
18F-FDG-PET showed progressive increases in
global brain glucose metabolism during cell therapy
(Figure 2).Case 3
Our case 3 was a 63-year-old man, with more than
20 years of formal education and maternal familiy
history of AD. He was diagnosed at the age ofFigure 2. Case 2. 18F-FDG-PET showing metabolic activity prior to
increase in cerebral metabolism can be seen at the end of cell therapy.61 years with dementia due to basal frontotemporal
atrophy. After demonstration of intracerebral beta-
amyloid neuritic plaques using 18F-Flutemetamol-
PET, a diagnosis of AD was made. He presented
important memory problems and disorientation epi-
sodes, which had caused him to stop working. He
had rejected donopezil. Cell therapy was adminis-
tered between November 2016 and May 2017
(100 million MSCs every 3 months). After first
administration, the patient experienced an ameliora-
tion, especially in orientation, corroborated by his
family. The benefit was progressive, and at the end
of the treatment, the patient could manage his fiscal
obligations and going out without any disorientation
problems. The family also reported better communi-
cation skills and evident greater participation in
interactions with family or friends. The patient
showed a score of 30 on MMSE [12] prior to the
treatment and maintained it at the end of treatment.
Neuropsychological assessment was performed
before the treatment (pre) and 2 weeks after each
MSCs administration (post 1, post 2 and post 3).
The data showed a statistically significant improve-
ment [17] in verbal learning [15]: pre, 28 points;
post 1, 32 points; post 2, 36 points; and post 3, 40
points; NAP = strong effect. Verbal short-term mem-
ory [15] showed the following: pre, 5 points; post 1,
6 points; post 2, 5 points; and post 3, 7 points;
NAP =medium effect. Verbal long-term memory
[15] showed the following: pre, 4 points; post 1, 8
points; post 2, 5 points; and post 3, 8 points;
NAP = strong effect. The study of semantic memory
[16] showed the following: pre, 25 points; post 1, 27
points; post 2, 26 points; and post 3, 29 points;
NAP = strong effect. Working memory [16] showed
the following: pre, 5 points; post 1, 10 points; post 2,cell therapy (AC) and at the end of treatment (DF). A clear
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effect. Study of inhibition [14] showed the following:
pre, 47 points; post 1, 54 points; post 2, 49 points;
and post 3, 58 points; NAP = strong effect.
In the course of cell therapy, injections of MSCs
induced a progressive increase in brain glucose
metabolism (Figure 3).
In May 2018, 1 year after the end of the cell ther-
apy, a new assessment was made. At this time,
MMSE score [12] was 26, and the patient showed
worse scores on verbal short-term memory [15], a
decrease of 2 points, but he got the same scores on
verbal learning [15] and long-term memory [15].
Furthermore, he presented a better performance on
semantic memory [16], working memory [16] and
inhibition [14]. On the other hand, at this time, brain
glucose metabolism decreased when compared with
the 18F-FDG-PET scan obtained at the end of treat-
ment, but the patient maintained the clinical
improvement that manifested in May 2017.Discussion
These cases are examples of patients in the early
stages of AD who experienced the arrest of clinical
deterioration or even clear improvement of their
symptoms after being treated using intrathecal injec-
tions of autologous MSCs. None of them received
any specific medication for disease at the time of
receiving cell therapy. In the three cases, improve-
ments were associated with significant neuropsycho-
logical improvements and with an increase inFigure 3. Case 3. (AC)Magnetic Resonance (MR) showing frontotemp
tamol-PET for detection of beta-amyloid neuritic plaques. (G) 18F-FDG
end of cell therapy. At this time, a strong increase of cerebral glucose metcerebral glucose metabolism, studied using 18F-
FDG-PET.
Cell therapy has been considered to be a possible
strategy in AD through neuroprotection and para-
crine actions [18,19], and diverse pre-clinical studies
with MSCs have shown benefit in rodent models of
AD [2022]. Moreover, in a clinical trial, umbilical
cord bloodderived (hUCB) MSCs were injected
into the hippocampus and precuneus of nine patients
with mild-to-moderate AD [23]. However, after a
review of clinical trials using cell therapy for AD,
there is no evidence for clinical usefulness [24].
Intrathecal administration of autologous MSCs is
safe and allows for the administration of a high num-
ber of cells to the whole brain [10], and our present
findings show that this type of cell therapy is associ-
ated with a clear increase in cerebral glucose metabo-
lism. It can explain early improvements better than if
improvement is attributed to cerebral neuroprotec-
tion or neurogenesis.
Due to the limited number of patients in our
present study, we can not draw conclusions about
the benefit of this type of cell therapy in AD, but it is
obvious that the relationship between the increase of
cerebral glucose metabolism and the intrathecal
administrations of autologous MSCs offers a new
line of research in the treatment of this disease,
mainly taking into account that an impaired brain
glucose metabolism is a commonly recognized early
feature of AD [25,26].
Our present findings should be confirmed in a
larger number of patients and multiple unknownsoral atrophy, predominantly on the left side. (DF) 18F-Fluteme-
-PET performed prior to cell therapy. (H) 18F-FDG-PET at the
abolism can be seen.
432 J. Vaquero et al.must be cleared, such as if the effect of the intrathe-
cal administration of MSCs is permanent, or the
convenience of a long-term periodic administration
of MSCs, in an attempt to maintain a possible thera-
peutic effect.Conclusions
Our present data suggest that intrathecal cell therapy
with autologous MSCs increases cerebral glucose
metabolism, being associated with neuropsychologi-
cal improvements in patients experiencing early
stages of AD. This type of cell therapy is safe, allow-
ing distribution of donor cells in the whole brain,
and its utility for the treatment of AD and other dis-
eases with cerebral impaired glucose metabolism
deserves further studies.Acknowledgments
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